#merck

[ follow ]
#keytruda #earnings-report #stock-analysis #price-target #costco #stock-market #investment #valuation #terns-pharma
Business
from24/7 Wall St.
3 days ago

Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds

Merck's earnings beat expectations, but shares fell due to acquisition charges, with a price target of $135.70 indicating potential upside.
from24/7 Wall St.
1 month ago

Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Costco's stock climbed from $844 in December 2025 to over $1,018, reflecting a premium valuation with a trailing P/E of 53x and a forward P/E of 50x.
Retirement
Healthcare
from24/7 Wall St.
3 months ago

Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

Merck reports Q4 2025 earnings Feb. 3 before market; Street expects $2.01 EPS on $16.12B revenue; Keytruda, Gardasil, guidance and Verona integration are focus.
Medicine
fromwww.bbc.com
7 months ago

Blow for UK drugs sector as Merck scraps 1bn expansion

Merck is cancelling a planned £1bn UK life‑sciences expansion, relocating research to the US and cutting UK jobs, citing insufficient UK investment and undervaluation of innovative medicines.
fromMedCity News
9 months ago

Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma - MedCity News

Merck has agreed to acquire Verona Pharma for $10 billion, gaining access to its first-in-class drug Ohtuvayre, which treats chronic obstructive pulmonary disease (COPD). This acquisition is crucial as Merck seeks assets amid an impending revenue drop from its top product losing patent protection.
Healthcare
[ Load more ]